Trending

#IRWD

Latest posts tagged with #IRWD on Bluesky

Latest Top
Trending

Posts tagged #IRWD

A dead tree trunk has fallen into the shallows of this pond.  A green heron sits on the end where it enters the water.  S/he is in profile and you can see the stringy light colored crown feathers jutting off the back of the head.  The heron has the typical navy blue/cream/navy blue/cream coloring on the head and a red eye.  The heavy bill is a matte black.  The body and wings are mostly gray with just a slight tinge of green toward the bottom of the bird.  The rest of the frame is filled with crisscrossing branches, green water plants, brown reeds, and reflections of all of the above.

A dead tree trunk has fallen into the shallows of this pond. A green heron sits on the end where it enters the water. S/he is in profile and you can see the stringy light colored crown feathers jutting off the back of the head. The heron has the typical navy blue/cream/navy blue/cream coloring on the head and a red eye. The heavy bill is a matte black. The body and wings are mostly gray with just a slight tinge of green toward the bottom of the bird. The rest of the frame is filled with crisscrossing branches, green water plants, brown reeds, and reflections of all of the above.

I'm enjoying this scene from the past weekend. A yellow-crowned night heron is on patrol at a pond. #IRWD #Birds #Nature #Photography #Herons

61 7 1 0

🚀 Shares surged after reaffirming guidance and also unveiling stronger FY26 revenue prospects (~$450M–$475M), beating consensus estimates.

💊 LINZESS continues to drive growth, with net sales expected to climb next year, helping boost investor confidence. #IRWD

Source: Yahoo Finance

0 0 0 0

#IRWD shares on the rise after crossing its long signal. Top gainers include IRWD, Ageagle Aerial Systems and other companies.

0 0 1 0

Today’s most cited tickers with positive sentiment (last 24h):

#TSLA: 20
#MU: 19
#SPY: 18
#NXXT: 14
#BE: 13
#DVLT: 12
#BIDU: 10
#RKLB: 10
#BTC: 9
#ONDS: 8
#ASTS: 8
#NVDA: 6
#SPX: 6
#ETH: 6
#UAVS: 6
#IRWD: 6
#IWM: 5
#GPUS: 5

1 0 0 0

News; ( NASDAQ: #IRWD ) Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

0 0 0 0
Video

📢 Stocks Trending NOW: #NVDA #TSLA #BIDU #ASML #UAVS #BABA #SMX #IRWD #MU #AMD

2 0 0 0
Preview
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal and rare diseases, today announced financial guidance for full year 2026.. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in...

#IRWD Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0

BREAKING NEWS: ( NASDAQ: #IRWD ) Hold Recommendation Issued On IRWD By Craig-Hallum

0 0 0 0

Pretty clear we are rotating into a new phase of the #stock #market where #biotech is leading (specifically Life Sciences/genomics). Initiated new position in #GRAL.
Watchlist: #IRWD #CMBM #PHAT #SNDX #APPN #TDC #VICR #CRK #LQDA.
#swing #trading

1 0 0 0
Preview
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit...

#IRWD Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0
Post image Post image Post image

Caspian Terns at the San Joaquin Marsh & Wildlife Santuary

#caspiantern #birds #nature #photography #om1markii #omsystem #IRWD

5 0 0 0
Ironwood Pharmaceuticals Q2 Earnings Reveal LINZESS Sales Surge 17% to $248M Amid Strategic Review LINZESS achieves 69% commercial margin with 10% prescription growth. Strategic alternatives review progresses as company evaluates valuable assets. See details.

#IRWD Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0
Preview
Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals reported Q1 2025 results with LINZESS prescription demand growing 8% year-over-year. Total revenue was $41.1 million, down from $74.9 million in Q1 2024. The company reported a GAAP net loss of $37.4 million ($0.23 per share). LINZESS U.S. net sales decreased 46% to $138.5 million, impacted by changes in AbbVie's gross-to-net rebate reserves. The company raised its adjusted EBITDA guidance to over $105 million for 2025 and announced it is exploring strategic alternatives with Goldman Sachs to maximize stockholder value. Ironwood maintains its 2025 guidance for U.S. LINZESS net sales of $800-$850 million and total revenue of $260-$290 million.

#IRWD Ironwood Pharmaceuticals Reports First Quarter 2025 Results

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0
Preview
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance Ironwood Pharmaceuticals (NASDAQ: IRWD) has maintained its 2025 guidance for LINZESS U.S. net sales at $800-$850 million and total revenue at $260-290 million, while raising its adjusted EBITDA guidance to over $105 million. The company reported strong LINZESS prescription demand growth of 8% year-over-year in Q1 2025, with 53 million capsules dispensed.However, Q1 2025 LINZESS U.S. net sales decreased 46% to $138.5 million compared to $256.6 million in Q1 2024, primarily due to a change in AbbVie's gross-to-net rebate reserves estimation. This adjustment is expected to impact quarterly phasing but not full-year results. The company anticipates that rebates owed in subsequent quarters will offset the Q1 2025 impact.

#IRWD Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0

BREAKING NEWS: ( NASDAQ: #IRWD ) Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

0 0 0 0
Preview
Ironwood's Apraglutide Faces FDA Setback: Strategic Review Launched After Trial Issues FDA demands new Phase 3 trial due to dosing issues, despite positive efficacy data. Ironwood initiates strategic review with Goldman Sachs. Full analysis inside.

#IRWD Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0
Preview
Can Ironwood's Massive 50% Staff Cuts Save Its Business After Revenue Decline? Ironwood reports $351.4M revenue with strategic reorganization expected to save $55-60M annually, despite 15% decrease in LINZESS sales to $916.3M.

#IRWD Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0
Preview
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future Ironwood Pharmaceuticals (NASDAQ: IRWD) announced significant corporate restructuring and updates on its apraglutide drug development. The company has initiated a rolling NDA submission for apraglutide in short bowel syndrome (SBS), with completion expected in Q3 2025. New data from the open-label extension study showed increased patient success in achieving enteral autonomy.The company is implementing a 50% workforce reduction, primarily affecting its field force, to optimize costs while maintaining LINZESS growth and supporting apraglutide development. The restructuring is expected to generate $55-60 million in annual operating expense savings.For FY2025, Ironwood projects LINZESS U.S. net sales of $800-850 million, total revenue of $260-290 million, and adjusted EBITDA exceeding $85 million. The company has also appointed Greg Martini as CFO and Tammi Gaskins as CCO to strengthen its leadership team.

#IRWD Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0

News; ( NASDAQ: #IRWD ) 3 Penny Stocks to Watch for Big Gains in 2025

#StockMarket #News

0 0 0 0

#IRWD Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0

#IRWD Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

www.stocktitan.net/news/IRWD/ironwood-pharm...

0 0 0 0

BREAKING NEWS: ( NASDAQ: #IRWD ) IRWD Price Target Alert: $12.00. Issued by Wells Fargo

#StockMarket #News

1 0 0 0